Valneva

Valneva

Develops, manufactures, and markets infectious-disease vaccines

Overview

Valneva SE develops, manufactures, and sells vaccines to prevent infectious diseases with unmet needs, including Lyme disease, COVID-19, and chikungunya, and it also supports travel health through vaccines and clinician education. Its vaccines progress from R&D through clinical trials to manufacturing and commercialization, with revenue coming from sales to healthcare providers and governments and possible public funding for development. The company differentiates itself with a focused portfolio of niche vaccines, strong engagement in travel health, and partnerships with governments and international organizations, together with an ESG-oriented approach. Its goal is to improve access to healthcare and patient safety by addressing critical public health needs with vaccine solutions.

About Valneva

Simplify's Rating
Why Valneva is rated
C
Rated C on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Government & Public Sector

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

Saint-Herblain, France

Founded

1999

Get referred to Valneva

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 2026 Phase 3 data showed VLA15/LB6V exceeded 70% efficacy without safety concerns.
  • Pfizer plans regulatory submissions in 2026, with decisions expected within twelve months.
  • Brazil approved local IXCHIQ production, and Shigella S4V2 Phase 2 data arrive mid-2026.

What critics are saying

  • H1 2026 revenue fell to €60.8 million, and Valneva cut guidance after weak travel demand.
  • FDA suspended IXCHIQ in 2025; Valneva withdrew U.S. filings in January 2026.
  • If Pfizer's Lyme filing stalls, Valneva loses its only near-term value-creating catalyst.

What makes Valneva unique

  • Only late-stage Lyme vaccine candidate, VLA15/LB6V, partnered with Pfizer and EMA PRIME.
  • Valneva runs three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ.
  • The company manufactures and commercializes its own vaccines, owning development-to-sales chain.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$930.6M

Above

Industry Average

Funded Over

17 Rounds

Private Placement Non VC funding comparison data is currently unavailable. We're working to provide this information soon!
Private Placement Non VC Funding Comparison
Coming Soon

Benefits

Hybrid Work Options

Wellness Program

Stock Options

Performance Bonus

Gym Membership

Stock Price

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo
Aug 14th, 2026
A Lyme disease vaccine may finally be on the way. Why did it take so long?

A Lyme disease vaccine may finally be on the way. Why did it take so long? Ellie Hutchings Updated Fri, August 14, 2026 at 4:00 a.m. PDT In 2009, there were only 144 reported human cases of Lyme disease in Canada. According to the most recent Public Health Agency of Canada (PHAC) data, there were 5,809 reported cases in 2024, and the preliminary number of cases for 2025 is 7,105. There's no denying Lyme disease is on the rise. Caused by the bacterium Borrelia burgdorferi and spread through the bite of infected blacklegged ticks, the disease can cause fatigue, rash, fever, chills and muscle aches, among other symptoms. If left untreated, the infection can spread to joints, the heart and the nervous system. Previously, a vaccine called LYMErix was administered to prevent Lyme disease. It was approved by the FDA in 1998, but withdrawn from the market just three years later, following reports of adverse reactions causing a lack of demand. Now, Lyme disease is treated with a course of antibiotics. But Lyme disease vaccines for dogs have been available for years, so why isn't there one for humans? Is there a Lyme disease vaccine for humans? No, there currently is no Lyme disease vaccine for humans. LYMErix was shelved in 2002, and there have been no new Lyme disease vaccines approved since. However, the pharmaceutical company Pfizer and French biotech firm Valneva are currently working together to develop a new vaccine, PF-07307405. As of March 2026, it has completed Phase 3 clinical trials. And Moderna is working on two more potential Lyme disease vaccines, called mRNA-1975 and mRNA-1982. These vaccines are not as far along in development as PF-07307405, and are both currently in Phase 2 clinical trials. What do we know about the Pfizer and Valneva vaccine? In March 2026, Pfizer and Valneva announced results from Phase 3 clinical trials of the Lyme disease vaccine they are co-developing. It demonstrated more than 70 per cent efficacy in preventing Lyme disease in individuals aged five years and above after four doses, with Pfizer now planning submissions to regulatory authorities. Annaliesa Anderson, senior vice president and chief vaccines officer at Pfizer, said in a news release that the result is "highly encouraging" and "creates confidence in the vaccine's potential to protect against this disease that can be debilitating." PF-07307405 works by causing a vaccinated person to create antibodies that are ingested by ticks when they bite them. These antibodies then inhibit the bacterium's ability to leave the tick, preventing it from being transmitted to the human host. Dr. Isaac Bogoch, a professor at the University of Toronto in the Department of Medicine and an infectious diseases specialist, tells National Post that while a Lyme disease vaccine is "definitely needed," the positive results from the Pfizer-Valneva aren't a sure indicator of success just yet. "It's already three doses and a booster, so let's just call it four doses," he says. "The more doses, the more challenges you're going to have with uptake and adherence. And if there are annual doses, and if it's expensive and inconvenient, I think that's going to limit the uptake." As for how long it could be until the vaccine rolls out, "that's the million dollar question," he says. At the moment, it's unclear whether regulatory agencies might ask for more clinical data or improvements. He adds that while the efficacy and side effect profile look good, "you don't really know until it's approved and it rolls out." "You can have the best phase three clinical study, but you're still going to be capped on the enrollment numbers, and until you see it used in a community, you won't have the most realistic picture," he says. What happened to the LYMErix vaccine? LYMErix was withdrawn by the manufacturer amid falling sales, prompted by widespread coverage of reported side effects and a class action lawsuit, despite the FDA determining it to be safe for public use. According to a scientific paper outlining the development and eventual shelving of the vaccine, which was published in the journal Epidemiology & Infection in 2006, LYMErix had nearly 80 per cent efficacy in preventing Lyme disease after three doses. However, the trial was conducted on subjects between 15 and 70 years old, meaning LYMErix was not approved for use on children. Around a year after LYMErix was first rolled out, reports of adverse reactions, including arthritis, began to circulate. A class-action suit against the developer, GlaxoSmithKline (GSK), which was called SmithKline Beecham at the time, was filed in 1999. By 2001, 1.4 million Lyme vaccine doses had been distributed in the U.S., and there were 59 reports of arthritis associated with vaccination. "The arthritis incidence in the patients receiving Lyme vaccine occurred at the same rate as the background in unvaccinated individuals," the paper explains. And after reviewing the Phase 3 trial that allowed the licensing of the vaccine, the FDA found no suggestion that LYMErix caused harm to its recipients. Nevertheless, press coverage of vaccine risks and ongoing litigation caused sales to fall dramatically and, in February 2002, GSK decided to withdraw LYMErix from the market. "Even though the regulatory agencies didn't find any proof that the vaccine caused arthritis, it just wasn't profitable," Bogoch says. "What's interesting, though, is a very similar vaccine is still used to this day for dogs." Why is it taking so long to develop a new Lyme disease vaccine? Only the vaccine manufacturers know the real answer to this question, says Bogoch. "Is it hard to make a vaccine? Of course. But it's not like there isn't the human capacity to come up with target candidates and a pipeline to develop this." He speculates that the fate of LYMErix may have disinclined manufacturers from developing a new Lyme disease vaccine. "Vaccine manufacturers are not just in the business of helping humanity; they're also in the business of making money," he says. "They might have seen the earlier challenges with the prior vaccine - how there was negative press associated with it and a limited market. And some of these decisions could have been driven by market demand as well." What else can be done to prevent Lyme disease? The best way to prevent contracting Lyme disease is to prevent tick bites. This can be done by wearing pants and long-sleeve shirts, using insect repellents and doing a tick check after being outdoors. Bogoch says insect repellents that contain 30 per cent DEET or 20 per cent Icaridin are usually the most effective. If you find a tick, remove it using a pair of tweezers to pull it out, rather than twisting or squeezing, which could leave the head behind and increase the chances of infection. "The infection isn't transmitted right away after a tick bite," explains Bogoch. "It actually takes 24 hours or more for the tick to be attached before Lyme is transmitted. If it's removed quickly enough, the risk of transmission is low." Meanwhile, pharmacists can prescribe antibiotic prophylaxis after exposure to prevent Lyme disease in provinces including Ontario, Quebec, New Brunswick and Nova Scotia. If you're worried, or you're experiencing symptoms, talk to your physician. Tests are available at provincial health laboratories, and treatment is a course of widely used antibiotics.

Investing.com
Aug 13th, 2026
Why is Valneva stock sliding today?

Why is Valneva stock sliding today? Published 08/13/2026, 04:39 AM (C) Reuters. Investing.com - Valneva stock is declining 1.9% to trade at €2.413 during today's session after the French specialty vaccine maker reported its first-half 2026 financial results, which showed a net loss of €63.3 million compared with a net loss of €20.8 million in the first half of 2025 - a deterioration driven by lower gross margins, reduced travel vaccine sales volumes, and one-off charges including IXCHIQ-related contract termination costs and inventory write-offs. The company also reported a drop in its first-half revenue and operating profit. Moreover, the print brought a guidance cut: Valneva revised its full-year 2026 product sales forecast to €135-€150 million from the prior range of €145-€160 million, with total revenues now expected between €145-€160 million, down from €155-€170 million. The company attributed the revision to an adverse trend in travel vaccine uptake across key markets linked to geopolitical factors. Broker Kempen noted in a research note that the decline was broadly in line with consensus expectations, and highlighted that upcoming milestones for the Lyme disease vaccine program - partnered with Pfizer - remain the key catalyst to watch. Adding to the downward pressure is a classic "sell the news" dynamic: Valneva shares had surged roughly 9% across the two sessions immediately preceding today's report as investors positioned ahead of the numbers, leaving the stock technically stretched heading into the release. The day's trading range of €2.292 to €2.416 reflects the initial volatility as the market digested the results, with the stock sitting well below its 52-week high of €5.415. Included in our AI-picked strategies -0.050 (-2.03%) Real-time Data On the broader market front, French equities have provided little support, with the CAC 40 having closed marginally lower in the prior session, while U.S. benchmarks are broadly flat today. Taken together, disappointing H1 financials, a guidance reduction, and the unwinding of pre-earnings optimism have combined to push Valneva lower, even as the company's restructuring progress and pipeline optionality - particularly around Lyme disease - continue to underpin longer-term analyst interest. Is VLS undervalued - or a trap? Gut instinct isn't enough. Our Fair Value calculator uses 17 proven valuation models to reveal what VLS is really worth. Get instant clarity on VLS - plus thousands of other stocks - before the opportunity disappears.

KPCW
Jun 27th, 2026
If a Lyme disease vaccine gets approved, how would it go over? We asked hunters.

If a Lyme disease vaccine gets approved, how would it go over? KPCW Radio asked hunters. KFF Health News | By Bram Sable-Smith Published June 27, 2026 at 4:30 AM MDT More and more Americans are being exposed to these parasites as climate change expands the range where they can survive. That means more people are also exposed to the bevy of health conditions they can cause, such as Rocky Mountain spotted fever, the alpha-gal-triggered red meat allergy, and, most common of all, Lyme disease. For the latter, there may be some additional protection on the horizon. Pharmaceutical companies Pfizer and Valneva announced this spring that they plan to seek regulatory approval for a vaccine to protect against Lyme disease. A previous vaccine for Lyme became available in the late 1990s but was pulled only three years later due to lawsuits, public fear of side effects, and a lack of interest. It's unclear whether this latest stab at a Lyme disease vaccine will get a warmer reception if it's approved, especially in the post-COVID era of vaccine skepticism. For a sense of how it might go over with rural populations at high risk of Lyme, KFF Health News spoke with a group of hunters. Few people spend more time in the woods exposed to ticks. At the same time, as a collective, hunters skew conservative, rural, and male, according to a survey from the Theodore Roosevelt Conservation Partnership. And these are identities associated with increased hesitancy about or resistance to vaccines, according to Ashley Kirzinger, associate director for Public Opinion and Survey Research at KFF, a health information nonprofit that includes KFF Health News. Targets for ticks. Left untreated, Lyme can cause a variety of symptoms, from fevers, chills, and headaches to arthritis, shooting pains, and inflammation of the brain and spinal cord, according to the Centers for Disease Control and Prevention. About 476,000 people in the U.S. may be diagnosed and treated for Lyme disease each year, the CDC says; that's at least in part because the range of places where cases have been reported has "expanded significantly" since 1995. So would hunters get the Lyme vaccine if it became available? "Given my proclivity for the outdoors, absolutely," said Jess Manganelli, one of seven hunters (and one hiker) who spoke with KFF Health News on a recent Saturday at the Busch Shooting Range in Weldon Spring, Missouri, just outside of St. Louis. Of the eight, Manganelli, who had been hunting turkeys the weekend before, was the most positive about the vaccine. Six others said they would consider it but would want more information about its safety and effectiveness as well as their risk for contracting the disease. But Manganelli was the only one who believed she may have previously contracted Lyme disease, although she was never formally diagnosed with it. Two years ago, she experienced muscle weakness, tiredness, fatigue, swelling, and headaches after a tick bite, but when she went to urgent care she was told they didn't test for Lyme. Nearly all the hunters knew someone who had had Lyme disease - an old roommate, a family member, friends, a former student. Lyme can be difficult to diagnose and to treat and is often misdiagnosed at first. Many of the hunters witnessed their acquaintances navigating those challenges and struggling with sometimes debilitating symptoms. An illness with lingering effects. That familiarity among the hunters in Missouri was unsurprising to author and conservationist Steven Rinella, host of the hunting show MeatEater. "I'm a turkey hunter. In talking about turkey hunting, you talk about ticks as much as you talk about turkeys," Rinella said. "Just the nature of turkey hunting puts you into exposure. You're sitting for long periods of time trying to use vegetation for concealment." In fact, both Rinella and his older son contracted Lyme disease 13 years ago during a bluegill fishing trip in the Hudson Valley in New York. His son developed Bell's palsy, a sudden paralysis on one side of the face, but recovered quickly after a course of oral antibiotics. Steven Rinella's symptoms, on the other hand, lingered for months, leaving him unable to walk down stairs without a handrail or to ride a bike. He ended up receiving intravenous antibiotic treatments for a month. "I thought my life had changed," Rinella said, "but I recovered, as far as I know." That experience is one reason Rinella said he would absolutely consider getting a Lyme vaccine if it proved safe and provided considerable protection against the disease. Unlike with some other diseases, prior infection does not provide permanent immunity, so a person who has had Lyme could still benefit from a vaccine. Knowledge of similar challenges influenced the thinking of the hunters in Missouri as well. Jeremy Hollingshead said he may be less inclined to take a vaccine owing to his former roommate's experience with Lyme disease, which is not to say the experience was pleasant. In fact, Hollingshead said he thinks his old pal is still dealing with lingering effects of it 10 years later. But Hollingshead has spent his whole life in the woods, and of hundreds of people he knows who have done the same, he knows of only one of them contracting Lyme. "I know it was a bad outcome for him," Hollingshead said, but he thinks the odds of getting Lyme himself seem pretty slim. Meanwhile, Julian Barnes said seeing a relative struggle with Lyme makes him more open to a potential vaccine. It took a long time for doctors to come to that diagnosis, and finding a good treatment has been equally difficult. "I would say I am vaccine-hesitant, generally speaking," Barnes said. "But Lyme, I've seen the way it affects people in my life." "I would definitely have to really understand the vaccine, how it works," Barnes added. An unclear path for a new vaccine. The new, four-dose vaccine candidate technically missed one of the bars set out in trials because not enough participants contracted Lyme. Still, the companies say it's about 75% effective in reducing cases, and they plan to submit it to regulators for approval. A Pfizer spokesperson said there were no updates on their regulatory efforts when contacted by KFF Health News in June. Health and Human Services Secretary Robert F. Kennedy Jr. was a noted anti-vaccine activist before taking over as head the agency that oversees vaccine approvals, and he's remade it in ways that have prompted some vaccine makers to pull back on development. But he's also been an advocate on Lyme disease. In May, he announced an initiative to combat Lyme disease. And during his Senate confirmation hearings, he said his family had been deeply affected by Lyme disease and that nobody would work harder than he would to find a vaccine or treatment. If the vaccine is ultimately approved by the FDA, an endorsement from Kennedy would go a long way, according to KFF's Kirzinger, particularly among supporters of his Make America Healthy Again movement, who tend to be more vaccine-skeptical. "They trust him as much as they trust their own doctors to tell them what to do with their health and for health information," Kirzinger said. "If he comes out as a strong proponent of this vaccine and says, 'Look what my administration did, and we made this available,' I would imagine there would be less vaccine resistance among that group." Only one of the hunters who spoke with KFF Health News said they definitely would not be interested in a Lyme vaccine if it became available. "I kind of hand it off to God and the body he gave me. I'm pretty durable," JP Cummings said. But even though he's not interested in it for himself, he's curious to see what his fellow hunters do as more information comes out. "Hunters care about the wildlife; hunters care about health," Cummings said. "They love the wildlife, they love their deer, and they love their fellow hunters." KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF.

WTJX
Jun 27th, 2026
If a Lyme disease vaccine gets approved, how would it go over? We asked hunters.

If a Lyme disease vaccine gets approved, how would it go over? Wtjx Newsfeed asked hunters. KFF Health News | By Bram Sable-Smith Published June 27, 2026 at 6:30 AM AST More and more Americans are being exposed to these parasites as climate change expands the range where they can survive. That means more people are also exposed to the bevy of health conditions they can cause, such as Rocky Mountain spotted fever, the alpha-gal-triggered red meat allergy, and, most common of all, Lyme disease. For the latter, there may be some additional protection on the horizon. Pharmaceutical companies Pfizer and Valneva announced this spring that they plan to seek regulatory approval for a vaccine to protect against Lyme disease. A previous vaccine for Lyme became available in the late 1990s but was pulled only three years later due to lawsuits, public fear of side effects, and a lack of interest. It's unclear whether this latest stab at a Lyme disease vaccine will get a warmer reception if it's approved, especially in the post-COVID era of vaccine skepticism. For a sense of how it might go over with rural populations at high risk of Lyme, KFF Health News spoke with a group of hunters. Few people spend more time in the woods exposed to ticks. At the same time, as a collective, hunters skew conservative, rural, and male, according to a survey from the Theodore Roosevelt Conservation Partnership. And these are identities associated with increased hesitancy about or resistance to vaccines, according to Ashley Kirzinger, associate director for Public Opinion and Survey Research at KFF, a health information nonprofit that includes KFF Health News. Targets for ticks. Left untreated, Lyme can cause a variety of symptoms, from fevers, chills, and headaches to arthritis, shooting pains, and inflammation of the brain and spinal cord, according to the Centers for Disease Control and Prevention. About 476,000 people in the U.S. may be diagnosed and treated for Lyme disease each year, the CDC says; that's at least in part because the range of places where cases have been reported has "expanded significantly" since 1995. So would hunters get the Lyme vaccine if it became available? "Given my proclivity for the outdoors, absolutely," said Jess Manganelli, one of seven hunters (and one hiker) who spoke with KFF Health News on a recent Saturday at the Busch Shooting Range in Weldon Spring, Missouri, just outside of St. Louis. Of the eight, Manganelli, who had been hunting turkeys the weekend before, was the most positive about the vaccine. Six others said they would consider it but would want more information about its safety and effectiveness as well as their risk for contracting the disease. But Manganelli was the only one who believed she may have previously contracted Lyme disease, although she was never formally diagnosed with it. Two years ago, she experienced muscle weakness, tiredness, fatigue, swelling, and headaches after a tick bite, but when she went to urgent care she was told they didn't test for Lyme. Nearly all the hunters knew someone who had had Lyme disease - an old roommate, a family member, friends, a former student. Lyme can be difficult to diagnose and to treat and is often misdiagnosed at first. Many of the hunters witnessed their acquaintances navigating those challenges and struggling with sometimes debilitating symptoms. An illness with lingering effects. That familiarity among the hunters in Missouri was unsurprising to author and conservationist Steven Rinella, host of the hunting show MeatEater. "I'm a turkey hunter. In talking about turkey hunting, you talk about ticks as much as you talk about turkeys," Rinella said. "Just the nature of turkey hunting puts you into exposure. You're sitting for long periods of time trying to use vegetation for concealment." In fact, both Rinella and his older son contracted Lyme disease 13 years ago during a bluegill fishing trip in the Hudson Valley in New York. His son developed Bell's palsy, a sudden paralysis on one side of the face, but recovered quickly after a course of oral antibiotics. Steven Rinella's symptoms, on the other hand, lingered for months, leaving him unable to walk down stairs without a handrail or to ride a bike. He ended up receiving intravenous antibiotic treatments for a month. "I thought my life had changed," Rinella said, "but I recovered, as far as I know." That experience is one reason Rinella said he would absolutely consider getting a Lyme vaccine if it proved safe and provided considerable protection against the disease. Unlike with some other diseases, prior infection does not provide permanent immunity, so a person who has had Lyme could still benefit from a vaccine. Knowledge of similar challenges influenced the thinking of the hunters in Missouri as well. Jeremy Hollingshead said he may be less inclined to take a vaccine owing to his former roommate's experience with Lyme disease, which is not to say the experience was pleasant. In fact, Hollingshead said he thinks his old pal is still dealing with lingering effects of it 10 years later. But Hollingshead has spent his whole life in the woods, and of hundreds of people he knows who have done the same, he knows of only one of them contracting Lyme. "I know it was a bad outcome for him," Hollingshead said, but he thinks the odds of getting Lyme himself seem pretty slim. Meanwhile, Julian Barnes said seeing a relative struggle with Lyme makes him more open to a potential vaccine. It took a long time for doctors to come to that diagnosis, and finding a good treatment has been equally difficult. "I would say I am vaccine-hesitant, generally speaking," Barnes said. "But Lyme, I've seen the way it affects people in my life." "I would definitely have to really understand the vaccine, how it works," Barnes added. An unclear path for a new vaccine. The new, four-dose vaccine candidate technically missed one of the bars set out in trials because not enough participants contracted Lyme. Still, the companies say it's about 75% effective in reducing cases, and they plan to submit it to regulators for approval. A Pfizer spokesperson said there were no updates on their regulatory efforts when contacted by KFF Health News in June. Health and Human Services Secretary Robert F. Kennedy Jr. was a noted anti-vaccine activist before taking over as head the agency that oversees vaccine approvals, and he's remade it in ways that have prompted some vaccine makers to pull back on development. But he's also been an advocate on Lyme disease. In May, he announced an initiative to combat Lyme disease. And during his Senate confirmation hearings, he said his family had been deeply affected by Lyme disease and that nobody would work harder than he would to find a vaccine or treatment. If the vaccine is ultimately approved by the FDA, an endorsement from Kennedy would go a long way, according to KFF's Kirzinger, particularly among supporters of his Make America Healthy Again movement, who tend to be more vaccine-skeptical. "They trust him as much as they trust their own doctors to tell them what to do with their health and for health information," Kirzinger said. "If he comes out as a strong proponent of this vaccine and says, 'Look what my administration did, and we made this available,' I would imagine there would be less vaccine resistance among that group." Only one of the hunters who spoke with KFF Health News said they definitely would not be interested in a Lyme vaccine if it became available. "I kind of hand it off to God and the body he gave me. I'm pretty durable," JP Cummings said. But even though he's not interested in it for himself, he's curious to see what his fellow hunters do as more information comes out. "Hunters care about the wildlife; hunters care about health," Cummings said. "They love the wildlife, they love their deer, and they love their fellow hunters." KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF.

Georgia Public Broadcasting
Jun 27th, 2026
If a Lyme disease vaccine gets approved, how would it go over? We asked hunters.

If a Lyme disease vaccine gets approved, how would it go over? Georgia Public Broadcasting asked hunters. June 27, 2026 6:30 AM * Bram Sable-Smith Primary content. Matthew Mealer holds up his targets at the Busch Shooting Range in Weldon Spring, Missouri, in May. Mealer said he's generally skeptical of new vaccines but might consider one for Lyme disease if it proves safe and effective. More and more Americans are being exposed to these parasites as climate change expands the range where they can survive. That means more people are also exposed to the bevy of health conditions they can cause, such as Rocky Mountain spotted fever, the alpha-gal-triggered red meat allergy, and, most common of all, Lyme disease. For the latter, there may be some additional protection on the horizon. Pharmaceutical companies Pfizer and Valneva announced this spring that they plan to seek regulatory approval for a vaccine to protect against Lyme disease. A previous vaccine for Lyme became available in the late 1990s but was pulled only three years later due to lawsuits, public fear of side effects, and a lack of interest. It's unclear whether this latest stab at a Lyme disease vaccine will get a warmer reception if it's approved, especially in the post-COVID era of vaccine skepticism. For a sense of how it might go over with rural populations at high risk of Lyme, KFF Health News spoke with a group of hunters. NPR HTML Block Few people spend more time in the woods exposed to ticks. At the same time, as a collective, hunters skew conservative, rural, and male, according to a survey from the Theodore Roosevelt Conservation Partnership. And these are identities associated with increased hesitancy about or resistance to vaccines, according to Ashley Kirzinger, associate director for Public Opinion and Survey Research at KFF, a health information nonprofit that includes KFF Health News. Targets for ticks. Left untreated, Lyme can cause a variety of symptoms, from fevers, chills, and headaches to arthritis, shooting pains, and inflammation of the brain and spinal cord, according to the Centers for Disease Control and Prevention. About 476,000 people in the U.S. may be diagnosed and treated for Lyme disease each year, the CDC says; that's at least in part because the range of places where cases have been reported has "expanded significantly" since 1995. So would hunters get the Lyme vaccine if it became available? "Given my proclivity for the outdoors, absolutely," said Jess Manganelli, one of seven hunters (and one hiker) who spoke with KFF Health News on a recent Saturday at the Busch Shooting Range in Weldon Spring, Missouri, just outside of St. Louis. Of the eight, Manganelli, who had been hunting turkeys the weekend before, was the most positive about the vaccine. Six others said they would consider it but would want more information about its safety and effectiveness as well as their risk for contracting the disease. But Manganelli was the only one who believed she may have previously contracted Lyme disease, although she was never formally diagnosed with it. Two years ago, she experienced muscle weakness, tiredness, fatigue, swelling, and headaches after a tick bite, but when she went to urgent care she was told they didn't test for Lyme. Nearly all the hunters knew someone who had had Lyme disease - an old roommate, a family member, friends, a former student. Lyme can be difficult to diagnose and to treat and is often misdiagnosed at first. Many of the hunters witnessed their acquaintances navigating those challenges and struggling with sometimes debilitating symptoms. An illness with lingering effects. That familiarity among the hunters in Missouri was unsurprising to author and conservationist Steven Rinella, host of the hunting show MeatEater. "I'm a turkey hunter. In talking about turkey hunting, you talk about ticks as much as you talk about turkeys," Rinella said. "Just the nature of turkey hunting puts you into exposure. You're sitting for long periods of time trying to use vegetation for concealment." In fact, both Rinella and his older son contracted Lyme disease 13 years ago during a bluegill fishing trip in the Hudson Valley in New York. His son developed Bell's palsy, a sudden paralysis on one side of the face, but recovered quickly after a course of oral antibiotics. Steven Rinella's symptoms, on the other hand, lingered for months, leaving him unable to walk down stairs without a handrail or to ride a bike. He ended up receiving intravenous antibiotic treatments for a month. "I thought my life had changed," Rinella said, "but I recovered, as far as I know." That experience is one reason Rinella said he would absolutely consider getting a Lyme vaccine if it proved safe and provided considerable protection against the disease. Unlike with some other diseases, prior infection does not provide permanent immunity, so a person who has had Lyme could still benefit from a vaccine. Knowledge of similar challenges influenced the thinking of the hunters in Missouri as well. Jeremy Hollingshead said he may be less inclined to take a vaccine owing to his former roommate's experience with Lyme disease, which is not to say the experience was pleasant. In fact, Hollingshead said he thinks his old pal is still dealing with lingering effects of it 10 years later. But Hollingshead has spent his whole life in the woods, and of hundreds of people he knows who have done the same, he knows of only one of them contracting Lyme. "I know it was a bad outcome for him," Hollingshead said, but he thinks the odds of getting Lyme himself seem pretty slim. Meanwhile, Julian Barnes said seeing a relative struggle with Lyme makes him more open to a potential vaccine. It took a long time for doctors to come to that diagnosis, and finding a good treatment has been equally difficult. "I would say I am vaccine-hesitant, generally speaking," Barnes said. "But Lyme, I've seen the way it affects people in my life." "I would definitely have to really understand the vaccine, how it works," Barnes added. An unclear path for a new vaccine. The new, four-dose vaccine candidate technically missed one of the bars set out in trials because not enough participants contracted Lyme. Still, the companies say it's about 75% effective in reducing cases, and they plan to submit it to regulators for approval. A Pfizer spokesperson said there were no updates on their regulatory efforts when contacted by KFF Health News in June. Health and Human Services Secretary Robert F. Kennedy Jr. was a noted anti-vaccine activist before taking over as head the agency that oversees vaccine approvals, and he's remade it in ways that have prompted some vaccine makers to pull back on development. But he's also been an advocate on Lyme disease. In May, he announced an initiative to combat Lyme disease. And during his Senate confirmation hearings, he said his family had been deeply affected by Lyme disease and that nobody would work harder than he would to find a vaccine or treatment. If the vaccine is ultimately approved by the FDA, an endorsement from Kennedy would go a long way, according to KFF's Kirzinger, particularly among supporters of his Make America Healthy Again movement, who tend to be more vaccine-skeptical. "They trust him as much as they trust their own doctors to tell them what to do with their health and for health information," Kirzinger said. "If he comes out as a strong proponent of this vaccine and says, 'Look what my administration did, and we made this available,' I would imagine there would be less vaccine resistance among that group." Only one of the hunters who spoke with KFF Health News said they definitely would not be interested in a Lyme vaccine if it became available. "I kind of hand it off to God and the body he gave me. I'm pretty durable," JP Cummings said. But even though he's not interested in it for himself, he's curious to see what his fellow hunters do as more information comes out. "Hunters care about the wildlife; hunters care about health," Cummings said. "They love the wildlife, they love their deer, and they love their fellow hunters." KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF. Bottom content. Support quality journalism. GPB is committed to bringing you comprehensive news coverage from Georgia, across the country and around the world. Your support makes this possible. Please consider making a gift today to support this vital public service.

Recently Posted Jobs

Sign up to get curated job recommendations

Valneva is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →